Alprenoxime
Alternative Names: CDDD 1815; HGP 5Latest Information Update: 07 Oct 1996
At a glance
- Originator Unknown
- Developer Pharmos Corporation
- Class Antiglaucomas
- Mechanism of Action Beta adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 07 Oct 1996 Discontinued-II for Glaucoma in USA (Ophthalmic)
- 15 Jul 1994 Phase-II clinical trials for Glaucoma in USA (Ophthalmic)